^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tazverik (tazemetostat)

    i
    Other names: EZM6438, IPN60200, EPZ-6438, E7438, EZ-438, E 7438, E-7438, EPZ6438, EPZ 6438, EZ438, EZ 438, EZM-6438, EZM 6438, IPN-60200, IPN 60200
    Company:
    Eisai, Hutchmed, Ipsen, Royalty
    Drug class:
    EZH2 inhibitor
    Related drugs:
    3d
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Suspended, University of Utah | Recruiting --> Suspended
    Trial suspension
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)
    3d
    A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (clinicaltrials.gov)
    P1, N=18, Terminated, Epizyme, Inc. | Recruiting --> Terminated; Ipsen decided to discontinue all active tazemetostat clinical trials.
    Trial termination
    |
    Tazverik (tazemetostat)
    7d
    Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=3, Terminated, Weill Medical College of Cornell University | N=38 --> 3 | Trial completion date: Dec 2028 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Feb 2026; Low accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Venclexta (venetoclax) • Tazverik (tazemetostat)
    7d
    Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=50 --> 23
    Enrollment closed • Enrollment change
    |
    EZH2 mutation
    |
    Tazverik (tazemetostat) • Lunsumio (mosunetuzumab-axgb)
    16d
    Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities. (PubMed, Curr Opin Oncol)
    Despite progress in understanding ES biology, treatment options are limited, and prognosis remains poor. Further studies are needed, but the rarity of the disease limits opportunities for conducting dedicated clinical trials or broader molecular characterization.
    Journal
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Tazverik (tazemetostat)
    16d
    Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC. (PubMed, J Med Chem)
    The study developed EIP103 as a first-in-class peptide degrader that targets EZH2 through multivalent, high-affinity interactions and induces conformational destabilization, representing a mechanism distinct from that of the small molecule inhibitor EPZ-6438...Additionally, molecular dynamics (MD) simulations and biochemical assays revealed that the peptide EIP103 binds to the SET domain of EZH2, altering its structure and triggering proteasomal degradation via Praja Ring Finger Ubiquitin Ligase 2 (PJA2)-mediated ubiquitination. Harboring both enzymatic inhibition and post-translational regulation properties, EIP103 exerts durable efficacy and activates antitumor immunity, making it a promising therapeutic candidate for TNBC.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    Tazverik (tazemetostat)
    23d
    Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation (clinicaltrials.gov)
    P2, N=20, Terminated, Prisma Health-Upstate | N=40 --> 20 | Trial completion date: Jan 2028 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Mar 2026; Ipsen has discontinued all active tazemetostat clinical trials and expanded access programs due to the emergence of a clinically unfavorable benefit risk profile for tazemetostat in combination with lenalidomide and rituximab.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Tazverik (tazemetostat)
    23d
    NCI-2022-03215: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | N=60 --> 18 | Trial primary completion date: Apr 2027 --> Feb 2026
    Enrollment change • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan
    23d
    NRG-GY014: Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    MSI-H/dMMR • ARID1A mutation
    |
    Tazverik (tazemetostat)
    27d
    NCI-2022-03215: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan
    28d
    ETCTN 10500: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    RAS wild-type • EZH2 mutation
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    1m
    CAIRE: Combining Epigenetic And Immune Therapy to Beat Cancer. (clinicaltrials.gov)
    P2, N=164, Completed, Institut Bergonié | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Jul 2025
    Trial completion • Trial completion date
    |
    MSI (Microsatellite instability) • IFNG (Interferon, gamma)
    |
    Imfinzi (durvalumab) • Tazverik (tazemetostat)